Blood test for Alzheimer’s highly accurate in large, international study

February 22, 2022

A blood test developed at Washington University School of Medicine in St. Louis has proven highly accurate in detecting early signs of Alzheimer’s disease in a study involving nearly 500 patients from across three continents, providing further evidence that the test should be considered for routine screening and diagnosis.

Innovation never stops

January 4, 2022

The startup culture in St. Louis has been strong since the early 2000s, particularly at Washington University in St. Louis, where many successful startups began or have an association, including Square, GiftAMeal, Varsity Tutors, Answers.com, Cardialen and Exegy. And it hasn’t slowed down: the venture capital firm M25 recently named St. Louis the fifth-best Midwest city for startups; St. Louis-based Arch Grants awarded 35 new startups with awards; and T-Rex awarded five $100,000 grants through its GeoSeed Grant Program. In 2020, St. Louis venture capital firm BioGenerator funded 22 startups in health care and agriculture.

Valo Health announces acquisition of Courier Therapeutics

July 27, 2021

A biotech­nol­o­gy com­pa­ny found­ed in 2015 by Dr. Alexan­der Krup­nick and col­leagues at Wash­ing­ton Uni­ver­si­ty in St. Louis and Mer­cury Fund, Couri­er devel­oped a pro­tein ther­a­peu­tics plat­form that has the poten­tial to make can­cer immunother­a­py safer and more effi­ca­cious than treat­ments cur­rent­ly avail­able or in devel­op­ment.

Arch Oncology secures $105 million Series C financing

April 27, 2021

“Arch Oncology’s highly differentiated approach to the development of anti-CD47 agents is a promising development in the immuno-oncology space,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology.